Abstract
The use of intermediate clinical endpoints and overall survival surrogates can shorten trial duration and related costs. This would potentially allow for an earlier introduction in practice of novel practice changing medications or treatments with a consequent impact on patient prognosis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
